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ABSTRACT
Vascular endothelial growth factor (VEGF), a potent angiogenic factor,
has been reported to be associated with a poor prognosis in primary
breast cancer and in several other cancer types. In the present study, we
have measured with ELISA the levels of VEGF in cytosolic extracts of 845
primary breast tumors of patients who developed a recurrence during
follow-up. All of the patients received tamoxifen (n 5 618) or cyclophos-
phamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil, Adria-
mycin, cyclophosphamide (FAC) chemotherapy (n 5 227) as first-line
systemic therapy after diagnosis of advanced disease. VEGF levels were
not related to age or menopausal status but were negatively related to the
cytosolic levels of estrogen receptor and progesterone receptor
(P < 0.0001). In patients who relapsed within 1 year after primary
surgery, tumor VEGF levels were higher than in patients who showed a
longer disease-free interval (P 5 0.0005). In patients with a first relapse in
the viscera, VEGF levels were higher compared with those that relapsed
to the bone or soft tissue (P 5 0.0004). In univariate analysis for response
to first-line tamoxifen therapy, patients with high or intermediate levels
showed a poor rate of response, compared with patients with low tumor-
VEGF levels (P 5 0.0001). Similarly, in multivariate analysis for response
to tamoxifen treatment, corrected for age, site of relapse, disease-free
interval, and estrogen receptor and progesterone receptor status, VEGF
status was an independent predictive factor (P 5 0.009). In concordance,
higher levels of VEGF were associated with a short progression-free
survival and postrelapse overall survival (both, P < 0.0001). On first-line
chemotherapy, the rate of response decreased with higher tumor levels of
VEGF, both in univariate (P 5 0.003) and in multivariate analysis
(P 5 0.004). Furthermore, higher VEGF levels were associated with a
short progression-free survival (P 5 0.003) and postrelapse overall sur-
vival (P 5 0.001). In conclusion, the tumor VEGF level is an important
independent marker that predicts a poor efficacy of both tamoxifen and
chemotherapy in advanced breast cancer. Knowledge of the tumor level of
VEGF might be helpful in selecting individual patients who may benefit
from treatments with antiangiogenic agents combined with conventionally
used drugs.
INTRODUCTION
Angiogenesis, required for tumor growth and metastasis (1, 2), is
balanced by a variety of positive and negative regulators of microves-
sel growth (3). An unbalance of these regulators results in a switch to
an angiogenic tumor phenotype (4–6). Quantification of MVD3 in
histological specimens of primary breast tumors and lymph-node
metastases was shown to be related to a poor RFS and overall survival
(7–10). VEGF, first described as vascular permeability factor (11),
consists of several splice variants yielding proteins of 121, 145, 165,
189, and 206 amino acids (12, 13). In tissue, VEGF165 is the predom-
inant isoform, and VEGF121 and VEGF165 are secreted into the
circulation (14). Within tumors the tumor cells are the main source of
VEGF; however, tumor-associated stroma has also been shown to
produce VEGF (15). VEGF behaves as a growth factor ligand that
binds to specific tyrosine kinase receptors VEGFR-1 (flt) and
VEGFR-2 (KDR/flk-1) on endothelial cells (16, 17).
In patients with breast cancer, serum and plasma VEGF levels have
been found to be elevated in patients with larger tumors and with
metastatic disease (18, 19). In human primary breast tumors, the
immunocytochemically assessed VEGF showed a close correlation
with MVD, and high expression levels were associated with a poor
relapse-free survival (20). The levels of VEGF measured by ELISA in
tumor cytosols correlated with microvessel count as well (21). How-
ever, in this small heterogeneous study including only 89 patients, the
level of cytosolic VEGF was not correlated with RFS (21). On the
other hand, several groups of investigators reported that an increased
expression level of VEGF mRNA (22) or protein, as measured by
ELISA in tumor cytosols (23–25), was associated with a poor prog-
nosis in primary breast cancer patients. Similarly, in patients treated
with adjuvant endocrine or chemotherapy, intratumoral MVD or a
high level of VEGF in primary breast tumor cytosols were shown to
be related to a poor prognosis (26–30). From these studies, however,
no conclusions can be drawn regarding the association of systemic
treatment with the level of VEGF or the extent of MVD because there
were no randomized untreated control groups available.
Recently, functional estrogen response elements in the gene coding
for VEGF have recently been reported (31, 32). There is evidence that
steroid hormones can regulate VEGF production in human breast
cancer cells. In human breast cancer cells in vitro (33, 34) and in
7,12-dimethylbenzanthracene-induced rat mammary tumors in vivo
(35), VEGF mRNA and/or protein production was found to be stim-
ulated by estrogens and progestins. The antiestrogen ICI 182.780
inhibited the estradiol-stimulated VEGF production of the MCF-7
breast cancer cells, whereas tamoxifen did not. Tamoxifen, when used
alone, even stimulated VEGF production by a mechanism thought to
be independent of ER (34). Currently no published data on the
relationship between the tumor level of VEGF and the efficacy of
response to systemic endocrine therapy, nor to chemotherapy, in
patients with advanced breast cancer are available. In the present
study, we aimed to assess in a relatively large series of patients
whether the tumor level of cytosolic VEGF might be predictive for the
efficacy of tamoxifen and/or chemotherapy in advanced breast cancer
patients.
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MATERIALS AND METHODS
Patients and Treatment. Our study design was approved by the medical
ethical committee of the Erasmus University Rotterdam, the Netherlands. A
series of 845 patients with primary operable breast cancer who underwent
resection of their primary tumor between 1978 and 1995, and who developed
a recurrence that was treated with first-line tamoxifen (618 patients) or chem-
otherapy (227 patients), were selected. At the time of surgery for their primary
tumor, the median age of the tamoxifen-treated patients was 59 years (range
26–90 years), and the chemotherapy-treated patients was 47 years (range
24–79 years). The differentiation grade of the tumor was based on histological
and cellular characteristics, as stated in the reports of the regional pathologists,
and it is not based on a central pathological review of all of the tumor samples
and, thus, reflects daily practice. The length of PFS was defined as the time
from the start of treatment of advanced disease until the start of next treatment
because of PD or until the time of intercurrent death. All of the patients were
assessed by standard Union International Contre Cancer criteria as having CR
and PR. Patients with no change for more than 6 months (SDis) have a PR-OS
similar to patients with PR (36, 37). Therefore, for overall response, objective
response (CR 1 PR) and SDis were combined.
First-Line Tamoxifen Treatment. All of the patients received tamoxifen
(40 mg daily) as first-line endocrine therapy after diagnosis of advanced
disease. None of the patients had received neoadjuvant therapy, and none of
the patients were exposed to hormonal treatment at an earlier stage (hormo-
naı¨ve). Adjuvant polychemotherapy was given to 117 patients (CMF in 76
patients, FAC in 41 patients). At start of tamoxifen treatment, 137 (22%)
patients were premenopausal and 481 (78%) patients were postmenopausal. Of
the patients, 523 (85%) had a an ER-positive ($10 fmol/mg of protein) tumor,
whereas 83 (13%) had an ER-negative tumor and 12 (2%) an unknown
receptor status. The median follow-up of the patients still alive after surgery is
93 months (range, 5–167 months) and after start of tamoxifen treatment is 39
months (range, 4–135 months). One hundred twenty-one patients are still
alive, whereas 497 (80%) died. On tamoxifen therapy given for advanced
disease, tumor progression occurred in 575 patients (93%) during follow-up.
Of these patients, 401 were subsequently treated with one or more additional
hormonal agents (mostly high-dose progestins), and, thus far, 330 patients
received systemic chemotherapy (mainly, CMF, or with Adriamycin instead of
methotrexate, FAC).
First-Line Chemotherapy. All of the patients received polychemotherapy
as first-line treatment (CMF in 111 and FAC in 116 patients) after diagnosis of
advanced disease. None of these patients had received neoadjuvant therapy.
Adjuvant chemotherapy was given to 44 patients (CMF in 31 patients, FAC in
13 patients) and adjuvant hormonal therapy was given to 44 patients as well,
either alone (42 patients) or in combination with CMF (2 patients). At start of
chemotherapy, 123 patients were premenopausal (54%) and 104 patients were
postmenopausal (46%). Of these patients, 123 (54%) had an ER-negative
tumor, whereas 101 (44%) had an ER-positive tumor and 3 (1%) an unknown
receptor status. The median follow-up of the patients still alive after surgery is
75 months (range, 13–118 months) and after start of chemotherapy is 18
months (range, 4–79 months). Thirty-three patients are still alive, and 194 died
(85%). On chemotherapy, tumor progression occurred in 215 patients (95%)
during follow-up. Of these patients, 142 were eventually treated with endo-
crine therapy, 106 (tamoxifen in 63 patients, progestins in 41 patients, others
in 2 patients) immediately after progression on first-line CMF or FAC and 36
after 1 to 3 additional chemotherapy regimens.
Tumors and Assays. Tumor tissues were stored in liquid nitrogen and
pulverized in the frozen state with a microdismembrator as recommended by
the EORTC for processing of breast tumor tissue for cytosolic ER and PgR
determinations (38). The resulting tissue powder was suspended in EORTC
receptor buffer [10 mM K2HPO4, containing 1.5 mM dipotassium EDTA, 3 mM
NaN3, 10 mM monothioglycerol, and 10% v/v glycerol (pH 7.4)]. The suspen-
sion was centrifuged for 30 min at 100,000 3 g at 4°C to obtain the supernatant
fraction (cytosol). ER and PgR levels were determined by ligand-binding assay
or enzyme immunoassay, as described previously (39).
VEGF levels were determined in breast tumor cytosols with an ELISA
developed by the EORTC Receptor and Biomarker Group. The assay specif-
ically measures VEGF165 and VEGF121, the main isoforms of VEGF. The
details of the assay procedure, including those of the specificity and perform-
ance, have been described elsewhere (40). To increase the sensitivity, modi-
fications involved the detecting procedures in which the horseradish peroxi-
dase-labeled goat antirabbit detecting antibody was replaced for monoclonal
antirabbit alkaline phosphatase-conjugated antibody (A-2556; Sigma Chemical
Co., St. Louis, MO). Incubation with the detecting antibody, 1:8000 diluted in
PBS, containing 1% w/v BSA and 0.1% v/v Tween 20, was performed for 2 h
at ambient temperature. Subsequent incubation with 100 ml of substrate solu-
tion, 0.1 mg/ml 4-methylumbelliferyl phosphate (free acid; Molecular Probes
Inc, Eugene, OR) in alkaline phosphatase buffer [0.1 M Tris-HCl, 0.1 M NaCl,
10 mM MgCl2 (pH 9.5)] and was performed for 1 h at ambient temperature.
The reaction was stopped with 150 ml of 0.15 M glycine (pH 10.5), and
fluorescence was measured with a fluorometric plate reader (Ascent FL Lab-
systems, Breda, The Netherlands). To enable the assessment of the between-
assay variations (% CV), in each of 32 assay-runs an aliquot of a pooled breast
cancer cytosol sample was analyzed. The between-assay CV was 12.6% and
the within-assay CV of samples measured in duplicate was 5.8% at a level of
0.88 ng/ml.
Statistics. The strength of the associations of VEGF with ER and PgR were
tested with Spearman rank correlation (rS). The associations of VEGF (used as
continuous variable) with other variables (used as grouping variables) was
tested with the nonparametric Wilcoxon rank-sum test or the Kruskal-Wallis
test, followed by a Wilcoxon-type test for trend across ordered groups if
appropriate. In uni- and multivariate analysis, the relation with response-to-
therapy was examined with logistic regression analysis. Multivariate analysis
was performed with variables eliminated in a step-down fashion. ORs were
calculated and presented with their 95% CIs. Variables with a P , 0.1 were
retained in the final multivariate models for response to tamoxifen and chem-
otherapy. The likelihood ratio test in regression models was used to test for
differences and for interactions. Isotonic regression analysis (41) was applied
to define cutpoints for VEGF after it had been established that, in a test for
trend using log-transformed VEGF values, high VEGF levels were signifi-
cantly associated with a poor rate of response or a shorter PFS on tamoxifen
therapy (P 5 0.002 and P 5 0.001, respectively), and chemotherapy
(P 5 0.003 and P 5 0.05, respectively). With isotonic regression analysis, the
hazard rate for failure is estimated as a function of the VEGF value under the
assumption of a monotone-decreasing failure rate (no response or progression)
with increasing VEGF levels. The cutpoints chosen to classify tumors as
VEGF-low, intermediate and -high, were 0.22 and 1.73 ng/mg of protein,
respectively, in analysis of response and survival on tamoxifen treatment. The
same cutpoints were adapted in the analysis of response and survival on
chemotherapy because there were no reasons to assume that they might be
different from those defined for the patients who were treated with tamoxifen.
Cox univariate regression analysis was used in the analysis of PFS and PR-OS.
The assumption of proportional hazards was verified graphically. RHRs were
calculated and presented with their 95% CIs. Survival curves were generated
using the method of Kaplan and Meier (42) and the log-rank test for trend was
used to examine survival data. All of the Ps are two-sided and relate to all of
the available data during the total period of follow-up.
RESULTS
Levels and Associations. The median level of VEGF determined
in 845 cytosols was 0.22 ng/mg of protein (range, 0–542 ng/mg
protein). Table 1 shows their median levels and quartiles in subgroups
of tumors and their relationships with patient and tumor characteris-
tics. The tumor levels of VEGF were not related to menopausal status
or with age (Spearman correlation, rs 5 0.05) at the time of primary
surgery. If the primary tumor had high levels of VEGF, the first
metastases more often developed in the viscera and bone, and less
frequently in soft tissues (P 5 0.0004). Patients who had a DFI of less
than 1 year had higher VEGF levels in the primary tumor than those
with a DFI of $1 year (P 5 0.0005). VEGF levels were higher in
hormone receptor-negative tumors compared with receptor-positive
tumors (rs 5 20.14 for ER, and rs 5 20.19 for PgR, respectively; for
both P , 0.0001). Tumor VEGF levels were not significantly corre-
lated with nodal status (P 5 0.09) or with primary tumor size
(P 5 0.51) or grade (P 5 0.20).
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Univariate Analysis for Response to Tamoxifen Therapy. Of
the 618 patients who received tamoxifen as first-line treatment for
advanced disease, 351 (57%) responded (29 CR, 83 PR, 239 SDis).
The median duration of response in these responders was 16.1
months.
Table 2 shows that postmenopausal and older patients had a higher
rate of response to tamoxifen treatment than premenopausal and
younger patients. Furthermore, patients who first relapsed to the
viscera showed a worse rate of response (51% response) compared
with patients of whom the soft tissue or the bone was the first site of
relapse (60 and 61% response, respectively). In patients with a DFI of
,1 year (40% response; OR set at 1) the fraction of responding
patients was smaller than in patients with a DFI of $1 year (63%
response; OR, 2.49). The application of adjuvant chemotherapy was
not related to the rate of response to tamoxifen treatment in advanced
disease. Patients with ER-positive or PgR-positive tumors had a
higher response rate (OR, 3.40 and 2.10, respectively) than patients
with ER-negative or PgR-negative tumors (OR, 1). Compared with
the 320 patients with low levels of VEGF (,0.22 ng/mg protein) in
the tumor cytosols [64% response (22% CR 1 PR and 42% SDis; OR,
1)], the 220 patients with intermediate VEGF levels ($0.22 and
,1.73 ng/mg protein) and the 78 patients with high VEGF levels
($1.73 ng/mg protein), showed a worse rate of response [intermedi-
ate, 52% response (16% CR 1 PR and 36% SDis; OR, 0.61); high,
40% response (9% CR 1 PR and 31% SDis; OR, 0.37); P 5 0.0001].
Lymph-node status, or size and grade of the primary tumor, which are
strong prognostic factors in patients with primary breast cancer, were
not significantly related to the rate of response to tamoxifen treatment
in patients with advanced disease. These factors were, therefore, not
further considered in the present study.
In Kaplan-Meier analysis of the 618 tamoxifen-treated patients,
those with intermediate and high VEGF levels showed a shorter PFS
(P , 0.0001; Fig. 1A) and PR-OS (P , 0.0001; Fig. 1B) compared
with patients with low VEGF levels. After 3 years, more than twice as
many patients were alive in cases in which the tumor had low VEGF
Table 1 Relationships of VEGF with patient and tumor characteristics
Characteristic Frequencya
VEGF
median value (quartiles)b P
All patients 845 0.22 (0.01, 0.82)
Menopausal statusc
Premenopausal 349 0.20 (0, 0.71)
Postmenopausal 496 0.24 (0.01, 0.98) 0.08d
First site of relapsee
Soft tissue 125 0.13 (0, 0.59)
Bone 335 0.18 (0, 0.61)
Viscera 385 0.30 (0.04, 1.13) 0.0004f
DFI
,1 yr 249 0.33 (0.04, 1.31)
$1 yr 596 0.20 (0, 0.72) 0.0005d
ER statusg
Negative 206 0.45 (0.06, 1.59)
Positive 624 0.18 (0, 64) ,0.0001g
PgR statush
Negative 283 0.36 (0.07, 1.40)
Positive 538 0.17 (0, 0.59) ,0.0001h
a Because of missing values, numbers do not always add up to 845.
b All of the values are in ng/mg of protein (25th and 75th percentiles).
c At time of primary surgery.
d P for Wilcoxon rank-sum test.
e In case of multiple sites, the site with the worst prognosis was considered dominant.
f P for Wilcoxon-type test for trend.
g P for Spearman rank correlation.
h Cutoff points used for ER and PgR: 10 fmol/mg of protein.
Table 2 Univariate and multivariate analysis for response to first-line tamoxifen therapy in patients with advanced breast cancer
Frequencya
Response
rate (%)
Univariate analysis Multivariate analysisc
Duration of
response (mo)d
Survival
(mo)eP ORb (95% CI)b P ORb (95% CI)b
All patients 618 57 16.1 26.2
Menopausal statusf
Premenopausal 137 47 1 16.3 25.9
Postmenopausal 481 60 0.007 1.69 (1.15–2.47) 16.1 26.2
Age (yr)f
#40 40 43 1 1 13.7 19.0
41–55 175 51 1.43 (0.72–2.87) 1.43 (0.68–2.99) 14.2 26.9
56–70 237 58 1.85 (0.94–3.65) 2.11 (1.02–4.34) 15.3 27.0
.70 166 64 0.02 2.45 (1.22–4.96) 0.008 2.78 (1.31–5.89) 18.5 26.1
First site of relapse
Soft tissue 92 60 1 1 16.3 31.4
Bone 287 61 1.05 (0.65–1.70) 0.80 (0.47–1.36) 17.3 30.4
Viscera 239 51 0.05 0.69 (0.42–1.12) 0.09 0.58 (0.34–1.00) 14.5 17.0
DFI
,1 yr 168 40 1 1 11.9 18.5
$1 yr 450 63 ,0.0001 2.49 (1.73–3.58) ,0.0001 2.30 (1.55–3.42) 16.8 31.1
Adjuvant therapy
No 484 56 1 16.3 26.0
Yes 134 59 0.57 1.12 (0.76–1.65) 14.8 27.0
ER statusg
Negative 83 31 1 1 12.7 13.6
Positive 523 61 ,0.0001 3.40 (2.07–5.58) 0.009 2.14 (1.20–3.83) 16.4 29.4
PgR statusg
Negative 155 43 1 1 12.5 17.0
Positive 442 62 ,0.0001 2.10 (1.45–3.05) 0.09 1.47 (0.95–2.28) 17.4 31.4
VEGF levelsh
Low 320 64 1 1 18.4 32.6
Intermediate 220 52 0.61 (0.43–0.87) 0.69 (0.47–1.00) 14.7 22.2
High 78 40 0.0001 0.37 (0.22–0.61) 0.009i 0.45 (0.26–0.78) 12.2 15.9
a Because of missing values, numbers do not always add up to 618.
b OR (95% CI).
c The final multivariate model with all of the factors known included 597 patients.
d Median time until progression (mo) in responding patients.
e PR-OS (mo) after start of first-line tamoxifen treatment of all 618 patients.
f At time of start of first-line tamoxifen treatment.
g Cutpoints: 10 fmol/mg protein.
h Low: ,0.22 ng/mg protein; intermediate: $0.22 and ,1.73 ng/mg protein; high: $1.73 ng/mg protein.
i The increment in x2 is 9.52.
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levels (46% alive) compared with those with high VEGF levels (20%
alive). The median PFS decreased from 9.9 months for those with low
VEGF levels, via 7.0 months for those with intermediate VEGF
levels, to 5.1 months for those with high levels of VEGF in the tumor
cytosols. Similarly, the PR-OS decreased from 32.6 months, via 22.2
months, to 15.9 months with VEGF levels increasing from low, via
intermediate, to high, respectively. The median duration of response
in the 351 patients responding to tamoxifen (Table 2) decreased from
18.4 months for patients with low (RHR, set at 1), via 14.7 months for
those with intermediate (RHR, 1.35; 95% CI, 1.06–1.71) to 12.2
months for those with high tumor levels of VEGF (RHR, 1.86; 95%
CI, 1.86–2.77; P 5 0.002). The median PR-OS in the 351 responding
patients decreased from 42.5 via 36.2 to 28.7 months for tumors with
low (RHR, 1), intermediate (RHR, 1.51; 95% CI, 1.16–1.98) and high
levels of VEGF (RHR, 1.94; 95% CI, 1.26–2.98), respectively
(P , 0.001).
Univariate Analysis for Response to Chemotherapy. Of the 227
patients treated with first-line chemotherapy, 120 (53%) responded
(16 CR, 67 PR, 37 SDis). The proportion of response was higher for
the 116 patients who received FAC (63% response; 8 CR, 45 PR, 20
SDis) than for the 111 patients who received CMF (42% response; 8
CR, 22 PR, 17 SDis; P 5 0.002). The median duration of response in
the 120 responding patients was 7.4 months; this was not different
between the patients who received FAC (7.6 months) or CMF (7.1
months).
Table 3 shows that on first-line chemotherapy, the premenopausal
patients responded more favorably (61% response) than the post-
menopausal patients (43% response). In patients with a DFI of ,1
year, the rate of response (44% response; OR, 1) was lower compared
with patients with a DFI of $1 year (58% response; OR, 1.69),
although not significant (P 5 0.06). The first site of relapse, the
application of former adjuvant systemic therapy, and the ER or PgR
status, were not related to the rate of response to first-line chemother-
apy. Higher levels of VEGF in the tumor cytosols predicted a poor
outcome on chemotherapy (P 5 0.003). Of the 101 patients with low
VEGF levels, 64% (43% CR 1 PR, 22% SDis; OR, 1) responded.
This compares with 48% responders (37% CR 1 PR, 10% SDis; OR,
0.50) in the 86 patients with intermediate VEGF levels, and to 35%
responders (20% CR 1 PR, 15% SDis; OR, 0.30) in the 40 patients
with high VEGF levels, respectively (Table 3). Lymph-node status, or
Fig. 1. PFS (A, C) and PR-OS (B, D) after the start of tamoxifen treatment (A, B) or chemotherapy (C, D) as a function of the level of VEGF: low, low values; interm., intermediate
values; high, high values. For cutpoints, see Table 2, Footnote h. The number of patients below the X-axis represents the number at risk in the low, intermediate, and high VEGF groups,
at the indicated time points.
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size and grade of the primary tumor, were not significantly related to
the rate of response to chemotherapy in patients with advanced
disease, and were not further considered in the present study.
In Kaplan-Meier analysis of the 227 patients who were treated with
chemotherapy, compared with tumors with low VEGF levels, those
with intermediate and high levels showed a shorter PFS (P 5 0.003;
Fig. 1C) and PR-OS (P 5 0.001; Fig. 1D). The median PFS and
PR-OS of all of the 227 patients decreased from 5.6 and 17.8 months
for those with low tumor VEGF levels, via 4.6 and 13.7 months for
those with intermediate VEGF levels, to 3.8 and 10.7 months for those
with high VEGF levels, respectively. The decrease in the median
duration of response on chemotherapy as a function of the VEGF level
in the 120 responding patients was not significantly affected. It
decreased from 7.6 months for those with low, via 7.1 months for
those with intermediate, to 6.6 months for those with high tumor
VEGF levels (Table 3; P 5 0.29). In PR-OS analysis of these
responding patients, compared with patients with low VEGF tumor
levels (RHR, 1), those with intermediate (RHR, 1.20; 95% CI, 0.78–
1.86) and high levels (RHR, 2.73; 95% CI, 1.49–5.00) showed a poor
survival (P 5 0.004). The median survival time in patients with high
VEGF levels was only 13.4 months, compared with 20.7 and 21.8
months for those with intermediate and low levels, respectively.
Multivariate Analysis for Response to Tamoxifen or Chemo-
therapy. The independent relationship of VEGF levels with the rate
of response to systemic treatment in advanced breast cancer was
studied using multivariate logistic regression analysis. In both the
analysis of response to tamoxifen treatment (Table 2) and the analysis
of response to chemotherapy (Table 3), corrected for the classical
variables, increasing levels of VEGF were significantly related to a
poor outcome of treatment (P 5 0.009 and P 5 0.004, respectively).
In addition to VEGF added as a categorical variable, young age, a
short DFI, and ER-negativity independently predicted a poor rate of
response to tamoxifen treatment as well. The contributions of the first
site of relapse and PgR to the multivariate model were not statistically
significant (both, P 5 0.09; Table 2). The marginal contribution of
PgR was attributable to the inclusion of ER in the model. In a separate
multivariate analysis in which VEGF was added to the model as a
log-transformed continuous variable instead of a categorical variable,
the contribution of VEGF was statistically significant as well
(P , 0.05). Furthermore, when ER and PgR were both included as
log-transformed continuous variables in the model (ER, P 5 0.004;
PgR, P 5 0.01), the contribution of VEGF as a categorical variable
was statistically significant (P 5 0.03). In this latter model, compared
with tumors with low VEGF levels (OR, 1), those with intermediate
and high levels had ORs and 95% CIs of 0.71 (0.48–1.04) and 0.49
(0.28–0.87), respectively. There were no statistically significant in-
teractions between VEGF and ER or PgR in the analysis of response
to tamoxifen treatment, neither when analyzed as continuous vari-
ables, nor when analyzed as categorical variables.
In the multivariate analysis for response to chemotherapy, in addi-
tion to VEGF added as a categorical variable (P 5 0.004), only
menopausal status was a significant predictor of a poor rate of re-
sponse (P 5 0.01), whereas the contribution of a short DFI was only
of borderline significance (P 5 0.08; Table 3). In a separate multi-
variate analysis in which VEGF was included as a log-transformed
continuous variable, its contribution was statistically significant as
well (OR, 0.86; 95% CI, 0.77–0.95; P 5 0.004). When the type of
chemotherapy (FAC or CMF) was additionally included as a covariate
in the model, the estimates of VEGF were not affected (OR, 0.86;
95% CI, 0.77–0.96; P 5 0.006). This suggests that the relationship of
Table 3 Univariate and multivariate analysis for response to first-line chemotherapy in patients with advanced breast cancer
Frequencya
Response
rate (%)
Univariate analysis Multivariate analysisc
Duration of
response (mo)d
Survival
(mo)eP ORb (95% CI)b P ORb (95% CI)b
All patients 227 53 7.4 14.3
Menopausal statusf
Premenopausal 123 61 1 1 7.0 18.1
Postmenopausal 104 43 0.008 0.49 (0.29–0.83) 0.01 0.49 (0.28–0.85) 8.5 11.7
Age (yr)f
#40 45 58 1 6.4 15.7
41–55 111 54 0.86 (0.43–1.73) 7.1 17.6
56–70 63 51 0.75 (0.35–1.63) 8.5 13.7
.70 8 25 0.36 0.24 (0.04–1.34) 4.5 4.7
First site of relapse
Soft tissue 33 52 1 5.4 17.6
Bone 48 54 1.11 (0.46–2.70) 7.4 19.9
Viscera 146 53 0.97 1.05 (0.49–2.24) 7.6 13.1
DFI
,1 yr 81 44 1 1 7.6 12.4
$1 yr 146 58 0.06 1.69 (0.98–2.93) 0.08 1.67 (0.94–2.96) 7.4 16.7
Adjuvant therapy
No 141 53 1 7.1 16.7
Yes 86 52 0.90 0.97 (0.56–1.65) 7.6 13.6
ER statusg
Negative 123 49 1 6.5 11.7
Positive 101 58 0.15 1.48 (0.87–2.51) 8.5 19.3
PgR statusg
Negative 128 48 1 6.6 11.3
Positive 96 59 0.10 1.56 (0.91–2.66) 7.6 20.0
VEGF levelsh
Low 101 64 1 1 7.6 17.8
Intermediate 86 48 0.50 (0.28–0.91) 0.48 (0.26–0.87) 7.1 13.7
High 40 35 0.003 0.30 (0.14–0.64) 0.004i 0.31 (0.14–0.68) 6.6 10.7
a Because of missing values, numbers do not always add up to 227.
b OR (95% CI).
c The final multivariate model included all 227 patients.
d Median time until progression (mo) in responding patients.
e PR-OS (mo) after start of first-line chemotherapy in all of the 227 patients.
f At time of start of chemotherapy.
g Cutpoints: 10 fmol/mg protein.
h Low: ,0.22 ng/mg protein; intermediate: $0.22 and ,1.73 ng/mg protein; high: $1.73 ng/mg protein.
i The increment in x2 is 11.0.
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VEGF to the rate of response to chemotherapy did not depend on the
presence of the anthracyclin in the polychemotherapy regimen given.
There were no statistically significant interactions between categori-
cally added ER (or PgR) and VEGF with respect to response to
chemotherapy. However, when analyzed as log-transformed continu-
ous variables in the multivariate analysis for response to chemother-
apy, there appeared to be a significant first-order interaction between
VEGF and ER (P 5 0.01), but not between VEGF and PgR
(P 5 0.14).
Response to Treatment in ER Subgroups. Because we observed
a statistically significant interaction of VEGF and ER with response to
chemotherapy, we performed exploratory analyses for the rate of
response in subgoups of ER-positive and ER-negative patients as a
function of VEGF status. The predictive value of VEGF for a poor
response to chemotherapy was confined to the subgroup of 123
ER-negative patients, i.e., intermediate and high levels of VEGF were
associated with a lower fraction of responding patients (P 5 0.026).
Compared with the 44 tumors with low VEGF levels (64% response;
OR, 1), the ORs and 95% CIs for the 51 tumors with intermediate
levels (45% response) was 0.46 (0.21–1.07), and for the 28 tumors
with high levels (32% response) was 0.27 (0.10–0.74), respectively.
In the 101 ER-positive patients, the decrease in the fraction of re-
sponders as a function of the level of VEGF (64, 53, and 45%
response for those with low, intermediate, and high VEGF levels,
respectively) was not statistically significant (P 5 0.37). In the
analysis of the rate of response to tamoxifen treatment as a function of
the level of VEGF, the association of VEGF with the fraction of
responders was confined to the subgroup of 523 ER-positive patients.
Of 285 patients with ER-positive and VEGF-low tumors, 192 (67%)
responded favorably (OR, 1). This compares with 101 (56% response)
of 180 tumors with intermediate VEGF levels (OR, 0.62; 95% CI,
0.42–0.91) and to 25 (43% response) of 58 tumors with high VEGF
levels (OR, 0.37; 95% CI, 0.21–0.65; P , 0.001). In 83 ER-negative
patients, the response rates were 31% for those with low, 34% with
intermediate, and 26% with high VEGF levels, respectively
(P 5 0.83).
DISCUSSION
Angiogenesis is a necessity for tumors to grow at the primary and
metastatic sites. Therefore, many new therapies aimed at the inhibi-
tion of angiogenesis, e.g., the use of natural inhibitors or drugs that
block VEGF action and VEGFR-associated tyrosine kinase activation,
are currently under investigation (reviewed in Refs. 3 and 43). Com-
binations of antiangiogenic drugs with conventional hormonal or
chemotherapeutic agents are attractive treatment options to explore
(44). For the selection of patients who may benefit from these com-
bined treatment modalities, knowledge of the tumor phenotype with
respect to the expression of potential target proteins, or pathways, is
essential. In preclinical breast cancer models, angiogenesis and/or
VEGF production may be regulated by hormones (26, 33–35, 45, 46)
or chemotherapeutic agents (47, 48). Furthermore, in human breast
tumors, a reduction in MVD was observed after treatment of patients
with neoadjuvant chemoendocrine therapy (49). Moreover, antiestro-
gens, including tamoxifen, have been shown to inhibit VEGF-stimu-
lated endothelial cell proliferation by a process not mediated by the
ER (50). Because VEGF is considered essential for tumor growth, and
because the VEGF-induced VEGFR tyrosine kinase activity could be
targeted in various ways, we have investigated in the present study
whether tumor VEGF levels are related to the efficacy of response to
tamoxifen and chemotherapy in advanced-breast-cancer patients.
The present finding that patients with a short DFI had significantly
higher tumor levels of VEGF as compared with those with a longer
DFI, is consistent with the results of earlier reports in which high
tumor levels of VEGF were found to be related to a poor prognosis in
primary breast cancer (20, 22–25). We observed in our study with 845
recurrences that the tumors that had metastasized to viscera as first
site of relapse had higher levels of VEGF as compared with those that
had metastasized to soft tissues or bone. These results are in accord-
ance with those recently reported by Linderholm et al. (30) in a study
involving 362 node-positive patients of whom 130 showed a recur-
rence during follow-up. However, although not comparable to the
results of VEGF measurements as performed by us and Linderholm et
al. (30), in an earlier study of Gasparini et al., including 254 node-
negative patients of whom 46 relapsed (51), no relationship between
MVD and first site of relapse was observed. There is no consensus in
the literature with respect to the association of VEGF with ER and/or
PgR. In the present study, we found significant but weak negative
correlations between the levels of VEGF and ER or PgR, in analogy
to some studies (28, 30) but in contrast to others (22, 23, 25). A
positive relationship between VEGF and ER expression has been
reported as well (19). It should be emphasized that, in this latter study,
VEGF and ER were assessed by immunohistochemistry, whereas in
the previous studies, tumor extracts were analyzed (22, 23, 25, 28,
30). The reasons for the discrepant findings may be the different
methodologies used to assess VEGF and hormone receptor levels and
the different patient populations included in the various studies (node-
negative, node-positive, unselected breast cancer patients, and pri-
mary and advanced breast cancer patients). These weak negative
correlations (or absence of correlations) between VEGF and ER and
PgR in the primary breast tumors is surprising in view of the evidence
that VEGF production in breast cancer cells is stimulated by estrogens
and progestins in vitro and/or in vivo (33–35). One plausible expla-
nation for this apparent discrepancy is that, in the extracts of homog-
enized breast tumor tissues, additional VEGF is present that is pro-
duced by noncancer cells such as fibroblasts (15, 52, 53) and
macrophages (54). In this respect, up-regulation of VEGF in mam-
mary fibroblasts in response to hypoxia, a major inducer of VEGF in
tumors (55), has been reported (56). A further explanation for the
observed lack of a positive relation between VEGF and ER and PgR
could be a constitutive expression of high levels of VEGF by ER-
negative breast cancer cells (57), whereas its expression is under the
control of estrogen in the better differentiated ER-positive breast
cancer cells. Moreover, VEGF gene expression is regulated by many
cytokines or growth factors (58), with expression levels that vary
widely between ER-positive and ER-negative breast cancer cells (59).
In univariate analysis of the efficacy of response on first-line
tamoxifen treatment in patients with advanced breast cancer, a high
level of tumor VEGF was significantly related to a poor outcome. In
multivariate analysis for response, this relationship remained signifi-
cant, even when corrected for classical predictive factors for response,
including hormone receptor status. Similarly, the duration of response
and the length of PFS and PR-OS were significantly reduced in
patients with high tumor levels of VEGF. In our exploratory analysis,
the predictive value of VEGF for the outcome on tamoxifen treatment
appeared to be confined to patients with ER-positive tumors. The
mechanisms by which high VEGF levels, or high angiogenesis, in
ER-positive tumors are associated with a poor outcome on tamoxifen
treatment can only be speculated on. Possible mechanisms that have
been put forward by Gasparini et al. (27), involve the production of
growth factors by stroma and vessels that stimulate the tumor cells
directly, such that the inhibitory effect of tamoxifen on tumor growth
is bypassed by paracrine tumor growth stimulatory pathways. Fur-
thermore, it was argued that stromal cells, such as macrophages,
produce growth factors that stimulate both the tumor and the vessels,
resulting in high angiogenesis with hormone resistance (27). A further
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possibility is that, under tamoxifen pressure, the tumor cells as well
produce growth factors that potentially stimulate, directly or indi-
rectly, angiogenesis. In this respect, tamoxifen has been shown to
increase tumor growth factor b1 expression by breast tumor cells
in vitro (60) as well as stromal fibroblasts in vivo (61). Tumor
growth factor b1 in its turn is capable of increasing VEGF pro-
duction by breast cancer cells (57) and breast tumor-associated
macrophages (62). Moreover, VEGF production increases to sup-
port the survival of endothelial cells under unfavorable conditions
(63), such as hypoxia (64) and high cell density (65). Therefore, it
is tempting to speculate that failure to respond to tamoxifen
treatment results in part from a stress (tamoxifen?)-induced endo-
thelial cell survival. Our present results on the relationship be-
tween VEGF and tamoxifen resistance in clinically advanced
breast cancer cannot directly be compared with those of others
because published data are lacking. There are two studies available
showing an adverse relationship between the primary tumor level
of VEGF and the length of RFS and OS after adjuvant tamoxifen
therapy in ER-positive node-positive primary breast cancer pa-
tients (28, 30). Furthermore, for this same patient group there are
two published studies showing an inverse association between
MVD and prognosis after adjuvant tamoxifen treatment (26, 27). In
all of these studies, the discriminatory power of VEGF or MVD
were of similar size as has been reported for untreated node-
negative breast cancer patients (8, 23–25). Therefore, from these
studies, no conclusion on the efficacy of adjuvant tamoxifen treat-
ment in relation to angiogenesis or VEGF expression can be made
because of the lack of direct comparison with untreated control
groups.
Similar to its association with a poor outcome on tamoxifen ther-
apy, we found high tumor-VEGF levels to be associated with a poor
rate of response and a short PFS and PR-OS, on chemotherapy given
for advanced breast cancer. In our exploratory analysis, this relation-
ship seemed to be confined to ER-negative tumors. Our results cannot
be compared with those in the literature because this is the first study
on tumor-VEGF levels and the efficacy of chemotherapy in advanced
breast cancer patients. There is, however, one study on the (lack of a)
relationship between MVD and the efficacy of doxorubicin mono-
therapy in patients with locally advanced breast cancer (66), and there
are a few studies (partly conflicting with respect to PFS and PR-OS)
available overall suggesting an adverse relation between MVD (28,
29, 67) or VEGF (30) and the efficacy of adjuvant polychemotherapy
in primary breast cancer. Similar to the studies exploring the relation-
ship between MVD or VEGF with the efficacy of adjuvant tamoxifen
treatment, these adjuvant chemotherapy studies are not conclusive as
well because no untreated control groups could be included. The
question remains why high tumor levels of VEGF are associated with
a poor response to chemotherapy in patients with advanced breast
cancer. One explanation could be that VEGF by inducing endothelial
cell proliferation indirectly contributes to the drug-resistant phenotype
of a tumor via the expression of drug-resistance-associated proteins
such as glutathione S-transferase-p (68).
In conclusion, our exploratory analysis suggests that for patients
with a high tumor-VEGF level, treatment with tamoxifen or chemo-
therapy alone may not prove to be beneficial to the patient with
advanced breast cancer. It seems reasonable to postulate that tumors
of this type may be responsive to angiogenesis inhibitors given alone
or in combination with conventional anticancer treatments. In partic-
ular, patients with ER-positive tumors, combined with high levels of
VEGF, might benefit from a combination of tamoxifen with an
antiangiogenic treatment.
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